Real-world approaches to outpatient treatment of status migrainosus: A survey study.
COVID‐19
corticosteroid
migraine
neuroleptic
treatment
triptan
Journal
Headache
ISSN: 1526-4610
Titre abrégé: Headache
Pays: United States
ID NLM: 2985091R
Informations de publication
Date de publication:
03 Jul 2024
03 Jul 2024
Historique:
revised:
16
04
2024
received:
13
03
2024
accepted:
21
04
2024
medline:
3
7
2024
pubmed:
3
7
2024
entrez:
3
7
2024
Statut:
aheadofprint
Résumé
Identify how the American Headache Society (AHS) membership manages status migrainosus (SM) among outpatients. SM is defined as a debilitating migraine attack lasting more than 72 h. There is no standard of care for SM, including whether a 72-h duration is required before the attack can be treated as SM. The Refractory Headache Special Interest Group from AHS developed a four-question survey distributed to AHS members enquiring (1) whether they treat severe refractory migraine attacks the same as SM regardless of duration, (2) what their first step in SM management is, (3) what the top three medications they use for SM are, and (4) whether they are United Council for Neurologic Subspecialties (UCNS) certified. The survey was conducted in January 2022. Descriptive statistical analyses were performed. Responses were received from 196 of 1859 (10.5%) AHS members; 64.3% were UCNS certified in headache management. Respondents treated 69.4% (136/196) of patients with a severe refractory migraine attack as SM before the 72-h period had elapsed. Most (76.0%, 149/196) chose "treat remotely using outpatient medications at home" as the first step, 11.2% (22/196) preferred procedures, 6.1% (12/196) favored an infusion center, 6.1% (12/196) sent patients to the emergency department (ED) or urgent care, and 0.5% (1/196) preferred direct hospital admission. The top five preferred medications were as follows: (1) corticosteroids (71.4%, 140/196), (2) nonsteroidal anti-inflammatory drugs (NSAIDs) (50.1%, 99/196), (3) neuroleptics (46.9%, 92/196), (4) triptans (30.6%, 60/196), and (5) dihydroergotamine (DHE) (21.4%, 42/196). Healthcare professionals with expertise in headache medicine typically treated severe migraine attacks early and did not wait 72 h to fulfill the diagnostic criteria for SM. Outpatient management with one or more medications for home use was preferred by most respondents; few opted for ED referrals. Finally, corticosteroids, NSAIDs, neuroleptics, triptans, and DHE were the top five preferred treatments for home SM management.
Sections du résumé
OBJECTIVES
OBJECTIVE
Identify how the American Headache Society (AHS) membership manages status migrainosus (SM) among outpatients.
BACKGROUND
BACKGROUND
SM is defined as a debilitating migraine attack lasting more than 72 h. There is no standard of care for SM, including whether a 72-h duration is required before the attack can be treated as SM.
METHODS
METHODS
The Refractory Headache Special Interest Group from AHS developed a four-question survey distributed to AHS members enquiring (1) whether they treat severe refractory migraine attacks the same as SM regardless of duration, (2) what their first step in SM management is, (3) what the top three medications they use for SM are, and (4) whether they are United Council for Neurologic Subspecialties (UCNS) certified. The survey was conducted in January 2022. Descriptive statistical analyses were performed.
RESULTS
RESULTS
Responses were received from 196 of 1859 (10.5%) AHS members; 64.3% were UCNS certified in headache management. Respondents treated 69.4% (136/196) of patients with a severe refractory migraine attack as SM before the 72-h period had elapsed. Most (76.0%, 149/196) chose "treat remotely using outpatient medications at home" as the first step, 11.2% (22/196) preferred procedures, 6.1% (12/196) favored an infusion center, 6.1% (12/196) sent patients to the emergency department (ED) or urgent care, and 0.5% (1/196) preferred direct hospital admission. The top five preferred medications were as follows: (1) corticosteroids (71.4%, 140/196), (2) nonsteroidal anti-inflammatory drugs (NSAIDs) (50.1%, 99/196), (3) neuroleptics (46.9%, 92/196), (4) triptans (30.6%, 60/196), and (5) dihydroergotamine (DHE) (21.4%, 42/196).
CONCLUSIONS
CONCLUSIONS
Healthcare professionals with expertise in headache medicine typically treated severe migraine attacks early and did not wait 72 h to fulfill the diagnostic criteria for SM. Outpatient management with one or more medications for home use was preferred by most respondents; few opted for ED referrals. Finally, corticosteroids, NSAIDs, neuroleptics, triptans, and DHE were the top five preferred treatments for home SM management.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Barrow Neurological Foundation
Informations de copyright
© 2024 American Headache Society.
Références
IHS. The International Classification of Headache Disorders, 3rd edition. Cephalgia. 2018;38:1‐211.
Beltramone M, Donnet A. Status migrainosus and migraine aura status in a French tertiary‐care center: an 11‐year retrospective analysis. Cephalalgia. 2014;34:633‐637.
Pryse‐Phillips W, Aube M, Bailey P, et al. A clinical study of migraine evolution. Headache. 2006;46:1480‐1486.
VanderPluym JH, Mangipudi K, Mbonde AA, et al. Incidence of status migrainosus in Olmsted County, Minnesota, United States: characterization and predictors of recurrence. Neurology. 2023;100:e255‐e263.
Iljazi A, Chua A, Rich‐Fiondella R, et al. Unrecognized challenges of treating status migrainosus: an observational study. Cephalalgia. 2020;40:818‐827.
Singh TD, Cutrer FM, Smith JH. Episodic status migrainosus: a novel migraine subtype. Cephalalgia. 2018;38:304‐311.
Orr SL. Status migrainosus: one of the most poorly understood but important complications of migraine. Neurology. 2022;100:107‐108.
Orr SL, Turner A, Kabbouche MA, et al. The profile and prognosis of youth with status migrainosus: results from an observational study. Headache. 2020;60:878‐888.
Modi SY, Dharaiya D, Katramados AM, Mitsias P. Predictors of prolonged hospital stay in status migrainosus. Neurohospitalist. 2016;6:141‐146.
Nelson GR, Bale JF, Kerr LM. Outcome and cost of inpatient hospitalization for intravenous dihydroergotamine treatment of refractory pediatric headache. Pediatr Neurol. 2017;66:76‐81.
Harnod T, Lin CL, Kao CH. Risk and predisposing factors for suicide attempts in patients with migraine and status migrainosus: a nationwide population‐based study. J Clin Med. 2018;7(9):269.
Couch JR Jr, Diamond S. Status migrainosus: causative and therapeutic aspects. Headache. 1983;23:94‐101.
Teodoro T, Ferreira J, Franco A, et al. Vertebral artery dissection mimicking status migrainosus. Am J Emerg Med. 2013;31(1721):e1723‐e1725.
Rodriguez Sainz A, Azkune Calle I, Ontanon JM, Gomez Beldarrain M, Garcia‐Monco JC. Bilateral carotid dissection presenting as status migrainosus: all that glitters is not gold. J Med Case. 2014;5(9)502‐504.
Shabas D, Sheikh HU, Gilad R. Pituitary apoplexy presenting as status migrainosus. Headache. 2017;57:641‐642.
Lanteri‐Minet M, Mick G, Allaf B. Early dosing and efficacy of triptans in acute migraine treatment: the TEMPO study. Cephalalgia. 2012;32:226‐235.
Goadsby PJ. The ‘Act when Mild’ (AwM) study: a step forward in our understanding of early treatment in acute migraine. Cephalalgia. 2008;28(Suppl 2):36‐41.
Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol. 2004;55:19‐26.
Australia M. Stigma survey: migraine stigma affects 94% of people living with migraine. 2020.
Strauss LD, Yugrakh MS, Kaplan KE, Minen MT, AHS Emergency Department IRSIG. Headache infusion centers: a survey on treatments provided, infusion center operations, and barriers to developing new infusion centers. Headache. 2021;61:1364‐1375.
Raskin NH. Treatment of status migrainosus: the American experience. Headache. 1990;30(Suppl 2):550‐553.
Orr SL, Friedman BW, Christie S, et al. Management of adults with acute migraine in the emergency department: the American Headache Society evidence assessment of parenteral pharmacotherapies. Headache. 2016;56:911‐940.
Ray JC, Chen Z, Ramsay G, Germaine J, Hutton EJ. Status migrainosus inpatient treatment with eptinezumab (SMITE): study protocol for a randomised controlled trial. BMJ Open. 2022;12:e059647.
Hoffman W, Aden J, Bossler R, Luster J, Jordan M. The association between hospital length of stay and treatment with IV magnesium in patients with status migrainosus. Neurohospitalist. 2021;11:235‐240.
Bigal ME, Bordini CA, Tepper SJ, Speciali JG. Intravenous magnesium sulphate in the acute treatment of migraine without aura and migraine with aura. A randomized, double‐blind, placebo‐controlled study. Cephalalgia. 2002;22:345‐353.
Xu F, Arakelyan A, Spitzberg A, et al. Experiences of an outpatient infusion center with intravenous magnesium therapy for status migrainosus. Clin Neurol Neurosurg. 2019;178:31‐35.
Utku U, Gokce M, Benli EM, Dinc A, Tuncel D. Intra‐venous chlorpromazine with fluid treatment in status migrainosus. Clin Neurol Neurosurg. 2014;119:4‐5.
Robbins MS, Wang D, DeOrchis VS. Methylprednisolone for status migrainous vertigo and cephalic status migrainosus. Headache. 2010;50:328.
Yanuck J, Nelson A, Jen M. Use of occipital nerve block in emergency department treatment of status migrainosus. Am J Emerg Med. 2018;36:1321.e1‐1321.e3.
Mehta D, Leary MC, Yacoub HA, et al. The effect of regional anesthetic sphenopalatine ganglion block on self‐reported pain in patients with status migrainosus. Headache. 2019;59:69‐76.
Zafar MS, Stewart AM, Toupin DN, Cook AM, Baumann RJ. Continuous intravenous valproate as abortive therapy for pediatric status migrainosus. Neurologist. 2018;23:43‐46.
De Simone R, Ranieri A, Ferra G, Cautiero F. Intravenous mannitol in status migrainosus treatment: a clinical case series. Neurol Sci. 2017;38:163‐167.
Farooq MU, Majid A, Pysh JJ, Kassab MY. Role of intravenous levetiracetam in status migrainosus. J Headache Pain. 2007;8:143‐144.
Wang SJ, Silberstein SD, Young WB. Droperidol treatment of status migrainosus and refractory migraine. Headache. 1997;37:377‐382.
Landsness EC, Wang LH, Bucelli RC. Ziprasidone as a potential abortive therapy for status migrainosus. Neurohospitalist. 2016;6:151‐156.
Haque N, Tariq N. Short term oral methylergonovine maleate prophylaxis for status migrainosus. Case series and review of literature. Front Neurol. 2019;10:201.
Poungvarin N. The first world report of botulinum A toxin injection for status migrainosus. J Med Assoc Thail. 2001;84:1199‐1203.
Udelsmann A, Saccomani P, Dreyer E, da Costa AL. Treatment of status migrainosus by general anesthesia: a case report. Braz J Anesthesiol. 2015;65:407‐410.
Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine–revised report of an EFNS task force. Eur J Neurol. 2009;16:968‐981.
Ailani J, Burch RC, Robbins MS, Board of Directors of the American Headache Society. The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;61:1021‐1039.
Orr SL, Aube M, Becker WJ, et al. Canadian Headache Society systematic review and recommendations on the treatment of migraine pain in emergency settings. Cephalalgia. 2015;35:271‐284.
Loder E, Geweke L. Volume and nature of telephone calls in a specialty headache practice. Headache. 2002;42:883‐887.
Brilla R, Woo KM, Seeger SK. Do headache patients require more care in between visits than other neurology outpatients? Headache. 2018;58:960‐963.
Szperka CL, Gelfand AA, Hershey AD. Patterns of use of peripheral nerve blocks and trigger point injections for pediatric headache: results of a survey of the American Headache Society Pediatric and Adolescent Section. Headache. 2016;56:1597‐1607.
Blumenfeld A, Ashkenazi A, Grosberg B, et al. Patterns of use of peripheral nerve blocks and trigger point injections among headache practitioners in the USA: results of the American headache society interventional procedure survey (AHS‐IPS). Headache. 2010;50:937‐942.
Yang S, Orlova Y, Lipe A, et al. Trends in the management of headache disorders in US emergency departments: analysis of 2007‐2018 National Hospital Ambulatory Medical Care Survey data. J Clin Med. 2022;11(5):1401.
Loder E, Weizenbaum E, Frishberg B, Silberstein S. Choosing wisely in headache medicine: the American Headache Society's list of five things physicians and patients should question. Headache. 2013;53:1651‐1659.
Bigal ME, Lipton RB. Overuse of acute migraine medications and migraine chronification. Curr Pain Headache Rep. 2009;13:301‐307.
Angus‐Leppan H, Guiloff AE, Benson K, Guiloff RJ. Navigating migraine care through the COVID‐19 pandemic: an update. J Neurol. 2021;268:4388‐4395.
Kato Y, Poh W, Horvath Z, Cadiou F, Shimazu T, Maruki Y. Impact of COVID‐19 pandemic on migraine management in the United States: insights from migraine tracking app users. BMC Neurol. 2021;21:345.
Robblee J, Starling AJ, Halker Singh RB, Riggins N. Teleneurology for primary headache disorders. Pract Neurol. 2020;31‐39.